Semaglutide is strictly for research purposes only, not for human or animal consumption.
Research highlights:
Glycemic Control: Significantly improves glycemic control in adults with type 2 diabetes by enhancing insulin secretion and lowering blood glucose levels.
Weight Loss: Demonstrates substantial weight loss effects, beneficial for overweight or obese individuals.
Cardiovascular Benefits: Shown to reduce cardiovascular risk factors, including lowering the risk of major adverse cardiovascular events.
Appetite Suppression: Reduces appetite and caloric intake, contributing to its effectiveness in weight management.
Long-acting Formulation: Administered as a once-weekly injection, providing convenience and improving patient adherence.
Reduction in HbA1c Levels: Proven to lower HbA1c levels more effectively than other GLP-1 receptor agonists and standard diabetes treatments.
Safety Profile: Generally well-tolerated with a favorable safety profile, with the most common side effects being gastrointestinal in nature.
Potential in NASH: Emerging evidence suggests potential benefits in treating nonalcoholic steatohepatitis (NASH) by reducing liver fat and inflammation.
Clinical Trials Success: Consistently demonstrates efficacy and safety in multiple large-scale clinical trials across diverse populations.
Broader Metabolic Benefits: Improves overall metabolic health, including better lipid profiles and reduced blood pressure, beyond glycemic control.
Product Information:
Molecular Formula: C187H291N45O59
Purity: >99.935%
Form: Lyophilized powder
